New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 11, 2013
14:25 EDTJNJ, JNJ, JNJ, MAKO, MAKO, MAKO, SYK, SYK, SYK, WMGI, WMGI, WMGI, ZMH, ZMH, ZMHLeerink's medical devices analyst holds a conference call
Medical Devices Analyst Newitter discusses new products, technologies and key focus topics/issues pertaining to the upcoming American Academy of Orthopaedic Surgeons (AAOS) 2013 Conference being held in Chicago (March 19-23) on an Analyst/Industry conference call to be held on March 14 at 3 pm.
News For JNJ;MAKO;SYK;WMGI;ZMH From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 21, 2014
09:27 EDTSYKRumors of Smith & Nephew bid from Stryker intensify, Daily Mail says
Shares of Smith & Nephew (SNN) rallied in U.K. trading amid "intensified" rumors that Stryker (SYK) will make a GBP 13B plus bid for its rival when its Takeover Panel restrictions are removed at month end, according to The Daily Mail's "This is Money." Reference Link
November 20, 2014
10:33 EDTZMHHigh option volume stocks
High option volume stocks: KBR LM PRGO CHRW DG ZMH LGF ZTS OSIR REGI
November 19, 2014
09:11 EDTZMHZimmer reports Synovasure PJI test earns certification
Subscribe for More Information
09:04 EDTJNJJohnson & Johnson submits NDA for three-month paliperidone palmitate
Janssen Research & Development, a Johnson & Johnson company, announced the submission of a New Drug Application, or NDA, for three-month atypical antipsychotic paliperidone palmitate to the FDA. The NDA seeks approval for the medication as a treatment for schizophrenia in adults. If approved, it will be the first and only long-acting atypical antipsychotic that has a four times a year dosing schedule.
06:30 EDTJNJJohnson & Johnson, Boston Scientific trial set to start tomorrow, Reuters says
Subscribe for More Information
November 18, 2014
09:56 EDTWMGIOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:30 EDTZMHZimmer agrees with EC to extend deal review deadline by 'limited number of days'
Zimmer Holdings announced that it has agreed with the European Commission to extend the deadline for the EC's review of Zimmer's proposed acquisition of Biomet by a "limited number of days" in order to provide the EC with certain additional information. Under the previous timeline, the EC had until March 11, 2015 to make a final decision on the proposed transaction. As a result of this extension, the deadline for the EC's final decision will be extended by the limited amount of additional time that Zimmer has agreed to provide to the EC. "Deadline extensions are not uncommon in such in-depth investigations. Zimmer has been working closely with the regulatory authorities to facilitate their review of the pending transaction and is encouraged by the substantial progress that has been made to date in connection with the overall regulatory process. Zimmer continues to expect to close the transaction in the first quarter of 2015," the company said.
05:35 EDTWMGIWright Medical upgraded to Overweight from Equal Weight at Barclays
Barclays upgraded Wright Medical (WMGI) to Overweight citing the recent underperformance of shares and its positive view of the Tornier (TRNX) acquisition. The firm raised its price target for shares to $37 from $36.
November 17, 2014
07:16 EDTJNJMilken Institute--Faster Cures to hold a conference
Subscribe for More Information
November 14, 2014
16:21 EDTJNJOn The Fly: Closing Wrap
Subscribe for More Information
14:53 EDTJNJCVS Express Scripts implementing drug price controls, says Cleveland Research
Cleveland Research believes that CVS (CVS) and Express scripts are implementing rebates and price controls on drug. The firm expects the companies to increase their focus on controlling durg prices next year, and adds that they have already itnroduced prior authorization criteria for hepatitis drug. Publicly traded drug companies include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Makers of hepatits c drugs include AbbVie (ABBV) and Gilead (GILD),
November 13, 2014
16:28 EDTJNJGeron announces global strategic collaboration with Janssen Biotech
Geron (GERN) announced that the company has entered into an exclusive worldwide license and collaboration agreement with Janssen Biotech, a Johnson & Johnson (JNJ) company, to develop and commercialize, imetelstat, Geron's telomerase inhibitor product candidate, for oncology, including hematologic malignancies, and other human therapeutics uses. Imetelstat is a modified oligonucleotide that is currently in early phase clinical development for myelofibrosis, or MF, and may have activity in other hematologic myeloid malignancies such as myelodysplastic syndrome, or MDS, and acute myelogenous leukemia, or AML. Under the terms of the agreement, Geron will receive an initial payment of $35M due after the applicable waiting periods under the Hart-Scott Rodino Act and is eligible to receive additional payments up to a potential total of $900M for the achievement of development, regulatory and commercial milestones, as well as royalties on worldwide net sales. Certain regulatory, development, manufacturing and promotional activities will be managed through a joint governance structure, with Janssen responsible for operational implementation of these activities. All sales will be booked by Janssen.
11:54 EDTJNJJanssen announces FDA approved sNDA for INVEGA SUSTENNA
Subscribe for More Information
10:44 EDTJNJMallinckrodt news on generic Concerta positive for Actavis, says BMO Capital
Subscribe for More Information
November 12, 2014
08:02 EDTWMGICredit Suisse to hold a conference
Subscribe for More Information
November 10, 2014
09:01 EDTZMHZimmer announces FDA clearance of Optio-C anterior cervical system
Subscribe for More Information
07:44 EDTJNJJohnson & Johnson looks for acquisitions to help expand in China, WSJ says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use